Charlotte Rouzaud Laborde

Charlotte Rouzaud Laborde

Auto-generated profile, based on publicly available information

Charlotte Rouzaud Laborde

National Institute of Health and Medical Research (INSERM) U1297–University of Toulouse, 31432 Toulouse Cedex 4, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2014 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
CRCharlotte Rouzaud‐Laborde
Charlotte Rouzaud‐Laborde
CDClement Delmas
Clement Delmas
NPNathalie Pizzinat
Nathalie Pizzinat
FTFlorence Tortosa
Florence Tortosa
CGCédric Garcia
Cédric Garcia
Olivier LairezOlivier Lairez
Olivier Lairez
Peripheral serotonin (5‐HT) has been involved in adverse cardiac remodeling and valve fibrosis. The peripheral levels of 5‐HT mainly depend on its release from activated platelets and degradation by monoamine oxidase A (MAO‐A). The SERAOPI study investigated the relationship between arterial serotoninergic system, degree of platelet activation and cardiac remodeling, in patients with aortic valve stenosis (AS). Thirty patients with severe AS and 15 control subjects underwent transthoracic echocardiography, radial, and aortic arterial blood sampling. Measurements of 5‐HT and its MAO‐A‐dependent degradation product, 5‐HIAA, were performed by HPLC. Arterial platelet activation was assessed by flow cytometry analysis of platelet surface expression of P‐selectin and activated integrin GPIIb/IIIa. Activated platelets and arterial plasma 5‐HT increased in AS patients as compared to control subjects (P‐selectin 1.08 ± 0.2MFI vs. 0.49 ± 0.1MFI, P = 0.04; GPIIb/IIIa 0.71 ± 0.1MFI vs. 0.35 ± 0.1MFI; P = 0.0015 and arterial plasma 5‐HT 11.55 ± 1.6 nM vs. 6.18 ± 0.7 nM, P = 0.028, respectively). Moreover, 5‐HT was strongly correlated to left ventricular hypertrophy assessed by echocardiography. The correlation was independent of cardiovascular risk comorbidities and others echocardiographic AS parameters. Finally, plasma 5‐HIAA increased in AS patients (74.64 ± 9.7 nM vs. 37.16 ± 4.1 nM; P = 0.0002) indicating a higher 5‐HT degradation rate by MAO‐A. Platelet activation, arterial circulating serotonin, and serotonin degradation increased in patients with AS. These observations suggest that the serotoninergic system may contribute to the pathogenesis of AS including valve fibrosis and adverse ventricular remodeling. Am. J. Hematol. 90:15–19, 2015.

14 July 2021 in JMIR Aging
Verified
Journal Article
Open access
CLCharlotte Rouzaud Laborde
Charlotte Rouzaud Laborde
ECErta Cenko
Erta Cenko
MMMamoun T Mardini
Mamoun T Mardini
SNSubhash Nerella
Subhash Nerella
MKMatin Kheirkhahan
Matin Kheirkhahan
TMTodd Manini
Todd Manini
Background: Smartwatches enable physicians to monitor symptoms in patients with knee osteoarthritis, their behavior, and their environment. Older adults experience fluctuations in their pain and related symptoms (mood, fatigue, and sleep quality) that smartwatches are ideally suited to capture remotely in a convenient manner. Objective: The aim of this study was to evaluate satisfaction, usability, and compliance using the real-time, online assessment and mobility monitoring (ROAMM) mobile app designed for smartwatches for individuals with knee osteoarthritis. Methods: Participants (N=28; mean age 73.2, SD 5.5 years; 70% female) with reported knee osteoarthritis were asked to wear a smartwatch with the ROAMM app installed. They were prompted to report their prior night’s sleep quality in the morning, followed by ecological momentary assessments (EMAs) of their pain, fatigue, mood, and activity in the morning, afternoon, and evening. Satisfaction, comfort, and usability were evaluated using a standardized questionnaire. Compliance with regard to answering EMAs was calculated after excluding time when the watch was not being worn for technical reasons (eg, while charging). Results: A majority of participants reported that the text displayed was large enough to read (22/26, 85%), and all participants found it easy to enter ratings using the smartwatch. Approximately half of the participants found the smartwatch to be comfortable (14/26, 54%) and would consider wearing it as their personal watch (11/24, 46%). Most participants were satisfied with its battery charging system (20/26, 77%). A majority of participants (19/26, 73%) expressed their willingness to use the ROAMM app for a 1-year research study. The overall EMA compliance rate was 83% (2505/3036 responses). The compliance rate was lower among those not regularly wearing a wristwatch (10/26, 88% vs 16/26, 71%) and among those who found the text too small to read (4/26, 86% vs 22/26, 60%). Conclusions: Older adults with knee osteoarthritis positively rated the ROAMM smartwatch app and were generally satisfied with the device. The high compliance rates coupled with the willingness to participate in a long-term study suggest that the ROAMM app is a viable approach to remotely collecting health symptoms and behaviors for both research and clinical endeavors.

15 August 2025 in Science Advances
Verified
Journal Article
Open access
Mathieu CinatoMathieu Cinato
Mathieu Cinato
RKRyeonshi Kang
Ryeonshi Kang
SKSolomiia Kramar
Solomiia Kramar
LSLesia Savchenko
Lesia Savchenko
NPNathalie Pizzinat
Nathalie Pizzinat
OKOksana Kunduzova
Oksana Kunduzova
Aberrant activation of fibroblasts is a pivotal component of cardiac fibrosis predisposing to heart failure. However, the molecular regulation of the functional state of cardiac fibroblasts in fibrosis resolution remains largely unexplored, and therefore, effective antifibrosis therapies are still lacking. By translating mouse transcriptomics to humans, we unlocked common molecular denominators connecting the fibroblast phenotypic state and fibrogenic signaling pathways in cardiac fibrosis. Through the construction of a fibroblast-specific transcriptional gene regulatory network, we found ITGAL and DUSP9 as key druggable targets for human myocardial fibrosis. A computational drug repurposing approach predicted 367 antifibrotic candidate compounds for heart disease. In primary cardiac fibroblasts derived from patients with heart failure, we provided experimental validation of the top 2–ranked repositioned drug candidates and their combination. These innovative approaches facilitate the identification of potential targets and drug candidates for cardiac fibrosis, providing actionable opportunities for clinical translation.

24 September 2015 in Journal of Evaluation in Clinical Practice
Verified
Journal Article
Closed access
PDF file
CRCharlotte Rouzaud‐Laborde
Charlotte Rouzaud‐Laborde
LDLéa Damery
Léa Damery
PCPhilippe Cestac
Philippe Cestac
BSBrigitte Sallerin
Brigitte Sallerin
PCPauline Calvet
Pauline Calvet

24 September 2020 in JMIR Preprints
Verified
Preprint
Open access
CLCharlotte Rouzaud Laborde
Charlotte Rouzaud Laborde
ECErta Cenko
Erta Cenko
MMMamoun T Mardini
Mamoun T Mardini
SNSubhash Nerella
Subhash Nerella
MKMatin Kheirkhahan
Matin Kheirkhahan
TMTodd Manini
Todd Manini
BACKGROUND Smartwatches enable physicians to monitor symptoms in patients with knee osteoarthritis, their behavior, and their environment. Older adults experience fluctuations in their pain and related symptoms (mood, fatigue, and sleep quality) that smartwatches are ideally suited to capture remotely in a convenient manner. OBJECTIVE The aim of this study was to evaluate satisfaction, usability, and compliance using the real-time, online assessment and mobility monitoring (ROAMM) mobile app designed for smartwatches for individuals with knee osteoarthritis. METHODS Participants (N=28; mean age 73.2, SD 5.5 years; 70% female) with reported knee osteoarthritis were asked to wear a smartwatch with the ROAMM app installed. They were prompted to report their prior night’s sleep quality in the morning, followed by ecological momentary assessments (EMAs) of their pain, fatigue, mood, and activity in the morning, afternoon, and evening. Satisfaction, comfort, and usability were evaluated using a standardized questionnaire. Compliance with regard to answering EMAs was calculated after excluding time when the watch was not being worn for technical reasons (eg, while charging). RESULTS A majority of participants reported that the text displayed was large enough to read (22/26, 85%), and all participants found it easy to enter ratings using the smartwatch. Approximately half of the participants found the smartwatch to be comfortable (14/26, 54%) and would consider wearing it as their personal watch (11/24, 46%). Most participants were satisfied with its battery charging system (20/26, 77%). A majority of participants (19/26, 73%) expressed their willingness to use the ROAMM app for a 1-year research study. The overall EMA compliance rate was 83% (2505/3036 responses). The compliance rate was lower among those not regularly wearing a wristwatch (10/26, 88% vs 16/26, 71%) and among those who found the text too small to read (4/26, 86% vs 22/26, 60%). CONCLUSIONS Older adults with knee osteoarthritis positively rated the ROAMM smartwatch app and were generally satisfied with the device. The high compliance rates coupled with the willingness to participate in a long-term study suggest that the ROAMM app is a viable approach to remotely collecting health symptoms and behaviors for both research and clinical endeavors.

27 January 2025 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
PNPauline Nardone
Pauline Nardone
SNSophie Nicolay
Sophie Nicolay
APAlix-Marie Pouget
Alix-Marie Pouget
ECElodie Civade
Elodie Civade
MSMathilde Strumia
Mathilde Strumia
CRCharlotte Laborde Rouzaud
Charlotte Laborde Rouzaud
Purpose More than 20% of prescription errors in hospitals are due to an incomplete medication history. Medication reconciliation is a solution to decrease unintentional discrepancies between medications taken at home and hospital prescriptions. It is a normalised clinical activity but it is time consuming. Medication reconciliation usually uses three sources of information for an optimised medical synthesis, one of which is the patient. A conversational robot for patients could be a solution to assist. Numerous digital applications are designed for patients and need to be tested for usability, satisfaction, reliability and time saved. Method We analysed Max, a conversational robot for patients scheduled for surgery in Toulouse University Hospital, using routinely collected health data in three successive steps. We examined willingness, compliance and patient satisfaction of usability with a Likert questionnaire and measured the time spent with Max and without. Finally, the reliability has been explored. Results The three successive observational steps were assessment of willingness and compliance (79 patients), time saved (61 patients) and reliability of the tool (68 patients). 71% agreed to use Max after a telephone call but only 73% of patients completed Max entirely. Max was well received and the overall satisfaction of usability was high for ease of use, readability, relevance and number of questions. Max saved a few minutes by optimised medical synthesis compared with a conventional telephone call. However, the reliability appeared to be lower than the human conventional telephone call. Randomised controlled trials are needed to confirm this feasibility study. Conclusion Max was appreciated by patients and appeared to be suitable for assisting pharmacists in medication reconciliation. The tool established the list of treatments taken by the patient at home but reliability appeared to be lower than a conventional telephone call, recommending a ‘double check’ on the patient’s arrival.